The regulatory frontier advancing cell and gene therapy policy in Singapore and beyond

“In a regulatory policy role, it is that curiosity that is important for keeping up with ever‑developing technologies: knowing what is out there, how it works, and what the potential side effects are.”

Wil Rich, Editor, Cell & Gene Therapy Insights , speaks with Eddie Tan Han Pin, Assistant Professor, Centre of Regulatory Excellence, Duke‑NUS Medical School, about his career journey from molecular cancer biology through GMP manufacturing and regulatory science into health policy, the evolving regulatory landscape for cell and gene therapies in Singapore and the Asia‑Pacific region, the role of regulatory reliance frameworks in broadening equitable patient access, and the transformative potential of AI across the cell and gene therapy development value chain.

Please enter your email to access content Read now